Monday, December 7, 2009

5AM Ventures closes $200M third fund

By Mass High Tech staff

Video Gallery

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

Breaking down the MIT $100K

Related News

UMass doles out $200K in research grants [March 15, 2010]

Pescatello named president of New England Biotech Association [March 15, 2010]

Rapid7 finds $2M in VC funding [March 15, 2010]

Rhythm launches to $21M Series A beat [March 15, 2010]

MHT Exclusive: Kleiner Perkins’ Ray Lane talks clean tech’s future in Boston [March 12, 2010]

Venture capital firm 5AM Venture Management LLC has closed its third fund at $200 million, the company announced today.

The firm, which has offices in both Waltham and Menlo Park, Calif., raised the fund from endowments, foundations, family offices, funds of funds and pension funds. It had listed initially raising $159 million in a July regulatory filing.

Founded in 2002 and focused on early stage life sciences companies, 5AM Ventures lists its managing partners as John Diekman, Scott Rocklage and Andy Schwab. Among its 27 investments, it has backed Lexington-based biotech Pulmatrix Inc.; Cambridge-based Semprus BioSciences Corp., an antibacterial coatings biomedical company; and California firms Relypsa Inc., Pearl Therapeutics and Ambrx Inc.